Jeffrey P. Hammel, MS

Director
Institute for Clinical Pharmacodynamics
Schenectady, New York, United States

Disclosure information not submitted.

Presentation(s):

• 569 - Identification of Ampicillin and Vancomycin In Vitro Susceptibility Test Interpretive Criteria for Enterococcus faecalis and Enterococcus faecium

  Wednesday, October 22, 2025
  11:06 AM - 11:18 AM US ET

• 570 - Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Ceftobiprole Continuous Infusion Dosing Regimens for Patients with Staphylococcus aureus Bacteremia (SAB)

  Wednesday, October 22, 2025
  11:18 AM - 11:30 AM US ET